[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Chengdu Kangnuoxing Biopharma,Inc.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":126},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,41,64,85,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100645137","phase-3-study-on-the-treatment-of-adolescent-patients-with-seasonal-allergic-rhinitis-100645137",false,"NCT07678931","Study on the Treatment of Adolescent Patients With Seasonal Allergic Rhinitis","A Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Adolescent Patients With Seasonal Allergic Rhinitis Receiving Background Therapy","Inclusion Criteria:\n\n* Age range: ≥12 years to \\\u003C18 years\n* Voluntarily sign the informed consent form.\n* Seasonal allergic rhinitis has been prevalent for at least 2 years.Positive for allergens associated with seasonal allergic rhinitis.\n* Poor control of seasonal allergic rhinitis with nasal glucocorticoids or other therapeutic agents during the same pollen season in the past.\n* Weight≥40kg.\n* Symptom severity scores for the season met the enrollment criteria.\n\nExclusion Criteria:\n\n* Subjects who received anti-interleukin-4 receptor alpha(anti-IL-4Rα), anti-thymic stromal lymphopoietin(anti-TSLP), anti-immunoglobulin E(anti-IgE) monoclonal antibodies or other biologics within 10 weeks or 5 half-lives prior to screening (whichever is longer), or have a history of inadequate therapeutic response or intolerance to prior anti-IL-4Rα monoclonal antibody treatment for seasonal allergic rhinitis.\n* Subjects with known hypersensitivity to stapokibart, any anti-IL-4Rα monoclonal antibody, or any ingredients of background concomitant medications.\n* Subjects who newly initiate allergen-specific immunotherapy within 3 months before screening or intend to receive such therapy during the trial, or whose allergen exposure at home or workplace is expected to change significantly throughout the study period.\n* Subjects with poorly controlled recent asthma or concomitant severe asthma with percent predicted Forced Expiratory Volume in one second(FEV1) ≤50% at screening.\n* Subjects presenting other active nasal comorbidities at screening (chronic rhinitis, drug-induced rhinitis, chronic rhinosinusitis with or without nasal polyps, severe nasal septal deviation, etc.) that may interfere with efficacy determination.\n* Subjects with current or past history of infections of special concern (active tuberculosis, helminthic infections, severe herpes virus infections, etc.), or diagnosed with malignant tumors within 5 years before screening, excluding fully cured cervical carcinoma in situ and non-metastatic cutaneous squamous or basal cell carcinoma.\n* Subjects with severe underlying medical conditions including severe hepatic and renal impairment, autoimmune diseases, cardiovascular and cerebrovascular disorders, HIV infection, active hepatitis B\u002FC, immunosuppression, or history of solid organ\u002Fhematopoietic stem cell transplantation which, in the investigator's opinion, may pose safety risks via trial participation.\n* Have a serious underlying medical condition that, in the opinion of the investigator, may pose a risk to subject safety by participation in a clinical trial.","ALL","12 Years","18 Years",{"count":20,"type":21},136,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study aimed at evaluating the efficacy and safety of stapokibart in adolescent patients with seasonal allergic rhinitis, and observing the quality of life, Pharmakokinetics(PK), Pharmacodynamics (PD) characteristics, and immunogenicity of subjects.",[27],"Seasonal Allergic Rhinitis (SAR)","NOT_YET_RECRUITING","2026-06-25",{"date":31,"type":32},"2026-07-01","ACTUAL",{"date":34,"type":21},"2026-08",{"date":36,"type":21},"2026-12",{"name":38,"class":39},"Chengdu Kangnuoxing Biopharma,Inc.","INDUSTRY",1,{"id":42,"slug":43,"hasResults":11,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":48,"targetDuration":50,"studyType":51,"phases":4,"briefSummary":52,"conditions":53,"keywords":4,"overallStatus":55,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":40},"100634836","a-study-of-stapokibart-injection-in-patients-with-atopic-dermatitis-ad-100634836","NCT07544862","A Study of Stapokibart Injection in Patients With Atopic Dermatitis (AD)","A Prospective Study of Stapokibart Injection in Patients With Moderate-to-Severe Atopic Dermatitis (AD)","Inclusion Criteria:\n\n* Trial participants aged 18 years or older at baseline, with no restrictions on gender.\n* Physician decision to treat trial participants with Stapokibart Injection for AD (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.\n\nExclusion Criteria:\n\n* Known history of allergic reaction to Stapokibart Injection.\n* Trial participants currently or plan participating in any interventional clinical trial.\n* Trial participants with hematologic malignancies.\n* Women with pregnant.\n* Any condition that, in the opinion of the investigator, may interfere with trial participants' ability to participate in the study.",{"count":49,"type":21},1000,"52 Weeks","OBSERVATIONAL","This study is an open label, prospective study to evaluate the safety and efficacy of Stapokibart Injection in patients with AD.",[54],"Atopic Dermatitis (AD)","RECRUITING","2026-06-08",{"date":58,"type":32},"2026-06-10",{"date":60,"type":32},"2026-06-02",{"date":62,"type":21},"2028-02",{"name":38,"class":39},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":75,"conditions":76,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":80,"completionDateStruct":82,"leadSponsor":84,"locationsCount":40},"100638021","phase-2-study-of-stapokibart-injection-in-adolescent-subjects-with-seasonal-allergic-rhinitis-sar-100638021","NCT07617324","Study of Stapokibart Injection in Adolescent Subjects With Seasonal Allergic Rhinitis (SAR)","A Multicenter, Single-arm, Open-label Study to Evaluate the Safety and Pharmacokinetics of Stapokibart Injection in Adolescent Patients With SAR Under Background Therapy","Inclusion Criteria:\n\n* Voluntarily sign the Informed Consent Form.\n* Age ≥ 12 years old and \\\u003C18 years old, weight ≥ 40 kg.\n* With a diagnosis of SAR, with or without allergic conjunctivitis, and the SAR duration was ≥ 2 years.\n\nExclusion Criteria:\n\n* Not enough washing-out period for previous therapies.\n* With other poorly controlled serious diseases or chronic conditions.\n* With any conditions that are not suitable for participation in this study by investigators.",{"count":72,"type":21},15,[74],"PHASE2","This study is a multicenter, single-arm, open-label, phase II study to evaluate the safety, pharmacokinetics, and immunogenicity of Stapokibart injection in Adolescent Patients with SAR.",[27],"2026-05-24",{"date":79,"type":32},"2026-06-01",{"date":81,"type":21},"2026-06",{"date":83,"type":21},"2027-02",{"name":38,"class":39},{"id":86,"slug":87,"hasResults":11,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":51,"phases":4,"briefSummary":94,"conditions":95,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":97,"lastUpdatePostDateStruct":98,"startDateStruct":100,"completionDateStruct":102,"leadSponsor":103,"locationsCount":40},"100628278","a-prospective-study-of-stapokibart-injection-in-patients-with-seasonal-allergic-rhinitis-sar-100628278","NCT07459556","A Prospective Study of Stapokibart Injection in Patients With Seasonal Allergic Rhinitis (SAR)","A Prospective Study of Stapokibart Injection in Patients With SAR","Inclusion Criteria:\n\n* Participants aged 18 years or older at the time of informed consent and provide voluntary informed consent to participate in the study before inclusion in the study.\n* Physician decision to treat the participant with Stapokibart Injection for SAR (according to the China-specific prescribing information) made prior to and independently of the participant's participation in the study.\n\nExclusion Criteria:\n\n* Known history of allergic reaction to Stapokibart Injection.\n* Participants currently or plan participating in any interventional clinical trial.\n* Participants with hematologic malignancies.\n* Women with pregnant.\n* Any condition that, in the opinion of the Investigator, may interfere with the participant's ability to participate in the study.",{"count":93,"type":21},400,"This study is an open label, prospective study to evaluate the safety of Stapokibart Injection in subjects with SAR.",[96],"SAR","2026-03-05",{"date":99,"type":32},"2026-03-09",{"date":101,"type":21},"2026-03",{"date":62,"type":21},{"name":38,"class":39},{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":18,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":22,"phases":114,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":40},"100609130","phase-3-study-of-stapokibart-injection-in-subjects-with-moderate-to-severe-bullous-pemphigoid-100609130","NCT07210554","Study of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid","A Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of Stapokibart Injection in Subjects With Moderate to Severe Bullous Pemphigoid","Inclusion Criteria:\n\n* Ability to understand the study content and voluntarily sign the Informed Consent Form (ICF).\n* Aged between 18 and 90 years, inclusive, regardless of gender.\n* Confirmed diagnosis of bullous pemphigoid prior to randomization.\n* Bullous Pemphigoid Disease Area Index (BPDAI) activity score ≥ 24 points at the screening visit and at randomization.\n* Weekly average of the Pruritus Numerical Rating Scale (NRS) score ≥ 4 points at randomization.\n* Karnofsky Performance Status score ≥50% at the screening visit.\n\nExclusion Criteria:\n\n* Diagnosis of other forms of pemphigoid or other autoimmune blistering diseases.\n* Presence of other active skin comorbidities that may interfere with the study evaluations, apart from bullous pemphigoid.\n* Insufficient washout period for prior treatments.\n* Any condition that, in the opinion of the investigator, would preclude the subject's participation in the study.","90 Years",{"count":113,"type":21},200,[24],"This study is a multicenter, randomized, double-blind, placebo-controlled phase III clinical study to evaluate the efficacy, safety, pharmacokinetics, pharmacodynamics, and immunogenicity of Stapokibart in subjects with Moderate to Severe Bullous Pemphigoid.",[117],"Bullous Pemphigoid (BP)","2025-09-30",{"date":120,"type":32},"2025-10-07",{"date":122,"type":21},"2025-11-11",{"date":124,"type":21},"2028-05-08",{"name":38,"class":39},""]